Pfizer seeks FDA approval for breast cancer drug palbociclib
The submission is expected to take place in the third quarter of 2014 based on discussions with the FDA regarding the final results of PALOMA-1, a randomized, Phase
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics.